DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Male Infertility Market Analysis By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay), By Treatment, And Segment Forecasts, 2014 - 2025" report to their offering.
The global male infertility market is expected to reach USD 4.7 billion by 2025. Globally, increasing infertility in males and advancements in diagnostic tests have been major factors driving the market growth. In addition, growing consciousness regarding factors causing male infertility and Assisted Reproductive Technology (ART) has led to increased adoption of treatment.
Furthermore, increasing aging population, rising obesity, and other lifestyle-associated diseases causing infertility are likely to boost the market during the forecast period. In the U.S., one third of infertility cases are due to female factor, one third due to male factors, and remaining one third are unexplained.
DNA fragmentation technique was the largest segment in male infertility tests market in 2016 and is expected to maintain its dominance during the forecast period due to rapid growth in next few years. High cost and increasing adoption in developed countries due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors for its dominance.
- EMD Sereno, Inc.
- Endo International plc
- Bayer Group
- SCSA Diagnostics, Inc.
- Andrology Solutions
- Halotech DNA SL
- Intas Pharmaceuticals Ltd.
- Aytu BioScience, Inc.
- Cadila Healthcare Ltd.
Key Topics Covered:
1. Methodology and Scope
2. Executive Summary
3. Male Infertility Industry Outlook
4. Male Infertility Market: Test Outlook
5. Male Infertility Market: Treatment Outlook
6. Male Infertility Market: Regional Outlook
7. Competitive Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/296tf5/male_infertility